Compare DRTS & UROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DRTS | UROY |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Israel | Canada |
| Employees | 121 | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 641.6M | 601.8M |
| IPO Year | N/A | N/A |
| Metric | DRTS | UROY |
|---|---|---|
| Price | $10.03 | $3.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | 698.4K | ★ 2.2M |
| Earning Date | 05-18-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $279.20 |
| Revenue Next Year | $699.98 | N/A |
| P/E Ratio | ★ N/A | $1,584.46 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.81 | $1.84 |
| 52 Week High | $10.81 | $5.52 |
| Indicator | DRTS | UROY |
|---|---|---|
| Relative Strength Index (RSI) | 64.43 | 42.81 |
| Support Level | $6.59 | $3.54 |
| Resistance Level | N/A | $4.07 |
| Average True Range (ATR) | 0.84 | 0.24 |
| MACD | 0.22 | -0.03 |
| Stochastic Oscillator | 78.69 | 5.52 |
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.